Page last updated: 2024-08-24

gemcitabine and elafin

gemcitabine has been researched along with elafin in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chao, SY; Chou, CH; Hour, TC; Hu, HT; Huang, AM; Kao, YT; Lin, PY; Liou, JY; Lu, CY; Pu, YS; Toh, S	1
Cao, XY; Hu, LP; Huo, YM; Jiang, SH; Jiang, YS; Li, J; Li, Q; Sun, YW; Tao, LY; Tian, GA; Wang, YH; Xiao, GG; Yang, MW; Yang, Q; Yang, XM; Zhang, XX; Zhang, YL; Zhang, ZG; Zhu, LL	1

Other Studies

2 other study(ies) available for gemcitabine and elafin

Article	Year
UBE2M-mediated p27(Kip1) degradation in gemcitabine cytotoxicity. Biochemical pharmacology, 2011, Jul-01, Volume: 82, Issue:1 Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Chromones; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Drug Screening Assays, Antitumor; Elafin; Formazans; Gemcitabine; Gene Expression Regulation; Gene Silencing; Humans; Morpholines; RNA, Small Interfering; Spectrometry, Mass, Electrospray Ionization; Tetrazolium Salts; Ubiquitins; Urinary Bladder Neoplasms	2011
Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 02-15, Volume: 25, Issue:4 Topics: Adenocarcinoma; Adenosine Triphosphate; Animals; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cell Survival; Clonal Evolution; Deoxycytidine; Elafin; Gemcitabine; Glycolysis; Heterografts; Humans; Mice; Oncogene Protein v-akt; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y2; RNA, Small Interfering; Sequence Analysis, RNA; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Microenvironment	2019

Article

Year

UBE2M-mediated p27(Kip1) degradation in gemcitabine cytotoxicity.

Biochemical pharmacology, 2011, Jul-01, Volume: 82, Issue:1

Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Chromones; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Drug Screening Assays, Antitumor; Elafin; Formazans; Gemcitabine; Gene Expression Regulation; Gene Silencing; Humans; Morpholines; RNA, Small Interfering; Spectrometry, Mass, Electrospray Ionization; Tetrazolium Salts; Ubiquitins; Urinary Bladder Neoplasms

2011

Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 02-15, Volume: 25, Issue:4

Topics: Adenocarcinoma; Adenosine Triphosphate; Animals; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cell Survival; Clonal Evolution; Deoxycytidine; Elafin; Gemcitabine; Glycolysis; Heterografts; Humans; Mice; Oncogene Protein v-akt; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y2; RNA, Small Interfering; Sequence Analysis, RNA; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Microenvironment

2019